<DOC>
	<DOCNO>NCT00917540</DOCNO>
	<brief_summary>The purpose present study develop biological prognostic index patient Binet stage A Chronic Lymphocytic Leukemia ( CLL ) necessitate therapy accord NCI guideline prospectively validate propose score system base absence/presence 1 , 2 3 unfavorable prognostic marker cluster differentiation 38 ( CD38 ) expression , Zap-70 expression immunoglobulin heavy chain variable region ( IgVH ) configuration .</brief_summary>
	<brief_title>Prospective Collection Biological Data Prognostic Relevance Patients With B-Cell Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>Clinical data include information disease localization laboratory parameter collect study entry , follow disease progression ( 36 month registration ) Biological marker evaluate centralized laboratory , study entry time disease progression ( 24 month follow-up non progress patient ) Using score system , patient separate 3 risk group : low-risk ( score 0 ) , intermediate-risk ( score 1 ) high-risk ( score 2-3 ) , significantly different clinical course .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Established diagnosis BCLL NCI criterion , perform local haematologist . ( Diagnosis confirm biological review committee accord flow cytometry analysis ( positive cluster differentiation antigen 5 ( CD5 ) , 19 ( CD19 ) ,23 ( CD23 ) ) . Age &gt; 18 year &lt; 70 year . Eastern Cooperative Oncology Group ( ECOG ) &lt; =2 . Binet stage A . Diagnosis perform within 12 month inclusion study . Patients necessitate therapy NCI guideline ( watch wait policy ) . Shipment peripheral blood sample centralize laboratory biological assessment . Clinical data include baseline information disease localization laboratory parameter stag assurance follow update least 3 year request . Written informed consent . Patients CLL whose diagnosis exceed 12 month registration . Patients leukemic phase lymphoproliferative disorder B origin CD5 and/or CD23 accord flow cytometry analysis . Clinical Binet stage B C. Patients necessitate therapy accord NCI guideline ( watch wait policy ) . Age &gt; 70 year . Without write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>